Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2018
Summary
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Cholesteryl ester transfer protein (CETP), also ca
- Introduction
- Global Markets Direct Report Coverage
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Overview
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development
- Chong Kun Dang Pharmaceutical Corp
- DalCor Pharmaceuticals Inc
- Kowa Co Ltd
- Pfizer Inc
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles
- CKD-508 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CKD-519 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dalcetrapib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- HL-16 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- K-312 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PF-04445597 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Products
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products
- Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones
- Featured News & Press Releases
- Apr 26, 2018: Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile
- Apr 05, 2018: DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial
- Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial
- Mar 07, 2017: DalCor's Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule
- Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans
- Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
- Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
- Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
- Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
- Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease
- Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds
- May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib
- Sep 13, 2011: Study Shows Efficacy Of Imaging Technology In Evaluating Heart Disease Drug Dalcetrapib
- Aug 29, 2011: Roche Announces Results From Two Exploratory Phase IIb Studies Of Dalcetrapib
- Apr 01, 2011: Roche Announces Dalcetrapib Phase II Studies dal-VESSEL And dal-PLAQUE Show Encouraging Results
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Indication, H2 2018
- Number of Products under Development by Companies, H2 2018
- Products under Development by Companies, H2 2018
- Number of Products under Investigation by Universities/Institutes, H2 2018
- Products under Investigation by Universities/Institutes, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Stage and Route of Administration, H2 2018
- Number of Products by Stage and Molecule Type, H2 2018
- Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
- Pipeline by DalCor Pharmaceuticals Inc, H2 2018
- Pipeline by Kowa Co Ltd, H2 2018
- Pipeline by Pfizer Inc, H2 2018
- Dormant Projects, H2 2018
- Discontinued Products, H2 2018
- Discontinued Products, H2 2018 (Contd..1), H2 2018
- List of Figures
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Top 10 Indications, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Stage and Route of Administration, H2 2018
- Number of Products by Stage and Molecule Type, H2 2018
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook